University at Buffalo participating in Regeneron clinical trial

Updated: November 20, 2020 11:09 PM
Created: November 20, 2020 10:19 PM

BUFFALO, N.Y. (WGRZ/WHEC) — The same antibody therapy that was administered to President Donald Trump is the subject of some clinical trials at the University at Buffalo.

It's a drug cocktail made by the company Regeneron.

It involves something called monoclonal antibodies, which are created in a lab, and which can stick to the spiked protein of the virus, possibly blocking its ability to multiply.

It's then injected into a patient.

The clinical trial is for people who don t have COVID-19, but who have been in close contact with someone who does, ideally, someone they live with, to see if it can give them some degree of immunity once they've been exposed.

"A small does and maybe that's all you need to stave off the virus," Dr. Sanjay Sethi said. "We got a lot of calls but unfortunately a lot of people were out of the window. They had been exposed but they had been exposed for more than four days."

From what they know, the antibodies are only effective if administered less than four days after exposure.

Copyright 2020 - WHEC-TV, LLC A Hubbard Broadcasting Company

Comment on Facebook